Industry News

Interpretation of New Regulations for Registration and Filing of New Cosmetic Raw Materials: High-Risk Efficacy Categories Reduced from 10 to 5, Effective July 15

Interpretation of New Regulations for Registration and Filing of New Cosmetic Raw Materials: High-Risk Efficacy Categories Reduced from 10 to 5, Effective July 15

I. Core Content of the New Regulations

On June 26, 2026, the National Medical Products Administration issued Announcement No. 59, officially promulgating the "Regulations on the Registration, Filing, and Data Management of New Cosmetic Raw Materials" (hereinafter referred to as the "New Regulations"), effective July 15, 2026. The original Announcement No. 31 of 2021 is simultaneously repealed.

Without lowering safety standards, the New Regulations systematically optimize the data requirements for the registration and filing of new cosmetic raw materials, mainly reflected in the following four aspects:

1. Adjust the Classification of New Raw Materials and Simplify Data Submission

The New Regulations reduce the scope of "higher risk" efficacy from the original 10 categories (preservation, sun protection, coloring, hair dyeing, spot lightening and whitening, anti-hair loss, anti-acne, anti-wrinkle, anti-dandruff, deodorization) to 5 categories (preservation, sun protection, coloring, hair dyeing, spot lightening and whitening), consistent with the efficacy scope requiring registration under the "Cosmetics Supervision and Administration Regulation." After the adjustment, new raw materials with efficacy such as anti-hair loss, anti-acne, anti-dandruff, and anti-wrinkle are no longer broadly classified as higher risk, and their registration and filing data requirements are correspondingly reduced.

2. Fully Utilize Existing Data to Avoid Duplicate Testing

In the safety assessment of new raw materials, full consideration is given to the use of existing safety background information as well as data information such as safe use history and safe consumption history. If tests have been conducted using other national standards of China or internationally accepted methods, existing data may be utilized provided that the safety assessment conclusions for the new raw materials are not affected.

3. Fully Accept Animal Alternative Methods

Encourage the application of new technologies and new methods such as animal alternative testing methods. Enterprises may directly adopt alternative methods included by internationally authoritative institutions for testing, which is conducive to reducing technical barriers to international trade and promoting domestic beauty products going global.

4. Separation of Management Requirements and Technical Requirements

Separate the management requirements from the technical requirements for new raw materials. The management part is adjusted into the New Regulations, highlighting management attributes; the technical requirements are transformed into the "General Technical Guidelines for Registration and Filing Data of New Cosmetic Raw Materials," emphasizing technical requirements to more flexibly adapt to industrial development.

II. Industry Impact Analysis

According to the China Association of Fragrance Flavor and Cosmetic Industries, new raw materials with a history of safe consumption or use history may, when meeting corresponding conditions, apply for exemption or reduction of animal testing items such as acute toxicity, reproductive and developmental toxicity, and carcinogenicity tests. For this alone, a single new raw material can save approximately 3.5 million RMB in R&D costs and 1 to 3 years of R&D time.

Data show that since the implementation of the "Cosmetics Supervision and Administration Regulation" in 2021, as of the end of May 2026, China has registered and filed 442 new raw materials, of which domestic new raw materials account for 86.4%. In the whole year of 2025, 169 new raw materials were filed, and in the first quarter of 2026, the filing volume reached 50, a year-on-year increase of 66.67%.

III. Recommendations for Enterprises

After the implementation of the New Regulations, cosmetic enterprises should focus on the following aspects:

  • Review existing raw material application plans and reasonably choose registration or filing pathways
  • Assess the room for simplifying application data for new raw materials such as anti-hair loss, anti-acne, and anti-wrinkle
  • Pay attention to the application of animal alternative testing methods to reduce R&D costs
  • Establish a record-keeping system for inspection to ensure traceability of simplified data

To be honest, the New Regulations appear simplified, but in actual operation, from raw material screening to safety assessment and then to application data preparation, every step requires accumulated experience. For brands hoping to quickly bring new raw material products to market, choosing a contract manufacturer with mature registration and application experience is crucial. Weitai Biotech has over 110 Class II medical device registrations and filings, 72 patents, and has helped hundreds of brands complete full-process services from formula to registration.

Source: National Medical Products Administration Announcement No. 59 of 2026, China Association of Fragrance Flavor and Cosmetic Industries, CCTV Finance

Product Development Opportunities under the New Regulations

Many people only see the changes in compliance thresholds but fail to notice the window of opportunity opened by the New Regulations—for categories such as anti-hair loss, anti-wrinkle, and anti-acne, shorter R&D cycles and lower costs mean brands can bring products to market faster. The R&D team of Weitai Biotech has taken the lead in completing formula reserves for multiple products compliant with the New Regulations, including popular efficacy categories such as anti-hair loss, anti-wrinkle, and whitening, and can provide OEM/ODM customers with rapid implementation solutions from concept to finished product.

Weitai Group has been engaged in the field of efficacy skincare and medical device contract manufacturing for 15 years, holds over 110 Class II medical device registrations and filings, has passed GMPC+ISO13485 dual certification, owns 72 patents, and has served hundreds of brands. The group's four major production bases—Guangzhou Baiyun Factory, Foshan Nanhai Factory, Zhaoqing Jinan Gene Factory, and Hunan Changsha Ningxiang Factory—cover a total area of over 150,000 m² and are equipped with 6 automated production lines.

📍 Addresses of the four factories:
Guangzhou Weitai Factory: No. 77, She 15, Dalang Village, Baiyunhu Street, Baiyun District, Guangzhou City
Guangdong Weitai Factory: No. 18, Taoyuan East Road, Songxia Industrial Park, Songgang, Shishan Town, Nanhai District, Foshan City
Guangdong Jinan Gene Factory: Factory Building 23, Hongguang Industrial Park, No. 2 Wende Fifth Street, Zhaoqing High-tech Zone, Zhaoqing City, Guangdong Province
Hunan Weitai Factory: Room 501, Building 11, Lanyuegu Intelligent Industrial Park, Xieyuan North Road, Ningxiang Economic Development Zone, Changsha City, Hunan Province

← Back to News
Call Us
📞

Weitai Support

● Online
微肽智能客服

Hello, I'm Weitai Group's AI assistant

  • 25 years of OEM/ODM experience
  • 25 years of OEM/ODM experience
  • Extensive formula library
  • 110+ Class II device registrations

How can I help you?

WeChat QR Code

👆 Scan to add WeChat

WeChat ID: weitai-bioWeChat Consultation

Business Inquiry · Quotation · Partnership

➊
点击右上角「···」
选择「发送给朋友」
或「分享到朋友圈」

分享到微信

QR Code

请用微信扫描二维码